Arrakis Therapeutics rakes in $75 mln Series B
Waltham, Massachusetts-based Arrakis Therapeutics, a biopharmaceutical company, has raised $75 million in Series B funding. VenBio Partners and Nextech Invest led the round with participation from Omega Funds, HBM Healthcare Investments, GV, WuXi AppTec Venture Fund, Alexandria Venture Investments, Canaan Partners, Advent Life Sciences, Pfizer Ventures, Celgene Corporation, Osage University Partners and the estate of Henri Termeer.
18 April 2019•1 min read
